Celsion
Corporation CLSN, a leading oncology drug development
company, today announced the presentation of Phase I results from the
Company's Phase I/II DIGNITY study of ThermoDox(R) in Breast Cancer
Recurrences at the Chest Wall at the ESMO 2012 Congress, the annual
conference for the European Society of Medical Oncology held in
Vienna, Austria September 28 to October 2, 2012. The presentation,
titled "Breast Cancer Recurrences at the Chest Wall (BCRCW) When
Standard Treatments (Tx) Have Failed: Lyso-thermosensitive liposomal
doxorubicin (LTLD) + Mild Local Hyperthermia (MLH)," was delivered by
Professor Hope S. Rugo, MD, from the UCSF School of Medicine, and
provided a clinical update of the Phase I/II DIGNITY trial studying
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in